IP Library › Granted Patent US 8,676,288
Granted Patent B2
US 8,676,288 · App. 13/166,685 · Granted Mar 18, 2014

Device and method for determining analyte levels

Inventors: Mark C. Shults (Madison, WI); Stuart J. Updike (Madison, WI); Rathbun K. Rhodes (Madison, WI)
Assignee: DexCom, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,676,288
App. No.
13/166,685
Granted
Mar 18, 2014
Kind
B2
Abstract

Devices and methods for determining analyte levels are described. The devices and methods allow for the implantation of analyte-monitoring devices, such as glucose monitoring devices, that result in the delivery of a dependable flow of blood to deliver sample to the implanted device. The devices comprise a unique microarchitectural arrangement in the sensor region that allows accurate data to be obtained over long periods of time.

Claims (34)

1. A device for measuring glucose in a bodily fluid, the device comprising:

a sensor operably connected to an electronic circuit and configured to continuously measure a signal associated with a glucose concentration in a host, the sensor comprising a working electrode and a reference electrode, wherein the working electrode and the reference electrode are configured for implantation in a subcutaneous tissue of the host; and

a membrane disposed on a portion of the sensor, configured to provide at least two phases of sensor function, wherein the at least two phases of sensor function comprise:

a first phase that occurs after implantation of the device in the subcutaneous tissue and during which the signal provides an unstable measurement of the glucose concentration in the host; and

a second phase that occurs after the first phase and during which the signal provides a stable measurement of the glucose concentration in the subcutaneous tissue of the host, wherein at least 95% of glucose concentration values measured by the signal are within 25% of one or reference glucose values over a period of time no less than 3 days in the subcutaneous tissue of the host, and wherein the one or more reference values are determined by analysis of the host's blood glucose;

wherein the device is configured to respond substantially linearly to changes in glucose concentration at a glucose concentration of up to about 400 mg/dL.

2. The device of claim 1 , wherein the membrane comprises an electrolyte layer, wherein the electrolyte layer comprises a flexible, hydrophilic material.

3. The device of claim 1 , wherein the membrane comprises a resistance layer comprising a semipermeable membrane configured to control a flux of oxygen and glucose therethrough.

4. The device of claim 1 , further comprising a housing filled with a material comprising a resin, wherein the resin secures the electronic circuit within the housing.

5. The device of claim 1 , further comprising an apparatus operatively connected to the electronic circuit and configured for transmitting data to a location external to the device.

6. The device of claim 5 , wherein the electronic circuit is configured to transmit data at intervals.

7. The device of claim 1 further comprising a housing comprising a cavity contained therewithin.

8. The device of claim 7 , wherein the sensor is situated within the housing cavity.

9. The device of claim 1 , wherein the membrane is configured to restrict passage of interfering species therethrough.

10. The device of claim 1 , wherein the membrane comprises a cross-linked polymer and is configured to control a flux of oxygen and glucose therethrough.

11. The device of claim 1 , wherein the sensor comprises an electrochemical mechanism.

12. The device of claim 1 , wherein the sensor comprises a non-enzymatic mechanism.

13. The device of claim 1 , wherein the sensor comprises a resonance mechanism.

14. The device of claim 1 , wherein the sensor comprises an acoustic wave mechanism.

15. The device of claim 1 , wherein the sensor comprises an optical mechanism.

16. The device of claim 1 , wherein the device is configured to provide stabilization of the membrane to reduce motion artifact.

17. A device for measuring glucose in a bodily fluid, the device comprising:

a sensor configured to generate a signal associated with a concentration of glucose in a host, wherein the sensor comprises a working electrode and a reference electrode, and wherein the working electrode and the reference electrode are configured for implantation in a subcutaneous tissue of the host; and

a membrane disposed on a portion of the sensor, wherein the membrane is configured to control a flux of oxygen and glucose therethrough;

wherein the device is configured, while implanted in the subcutaneous tissue of the host, to respond substantially linearly to changes in glucose concentration at a glucose level up to 400 mg/dL, wherein the membrane provides for at least 95% of glucose concentration values measured by the signal being within 25% of one or more reference glucose values for a useful life of the device of no less than 3 days in the subcutaneous tissue of the host, and wherein the reference values are determined by analysis of the host's blood glucose.

18. The device of claim 17 , wherein the device further comprises an apparatus configured to transmit data to a location external to the device.

19. The device of claim 17 , wherein the membrane comprises an electrolyte layer, wherein the electrolyte layer comprises a flexible, hydrophilic material.

20. The device of claim 17 , wherein the membrane is configured to restrict passage of interfering species therethrough.

21. The device of claim 17 , wherein the sensor comprises an electrochemical mechanism.

22. The device of claim 17 , wherein the sensor comprises a non-enzymatic mechanism.

23. The device of claim 17 , wherein the sensor comprises a resonance mechanism.

24. The device of claim 17 , wherein the sensor comprises an acoustic wave mechanism.

25. The device of claim 17 , wherein the sensor comprises an optical mechanism.

26. The device of claim 17 , wherein the device is configured to provide stabilization of the membrane to reduce motion artifact.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2011
From: MARKWELL MEDICAL INSTITUTE, INC.
To: DEXCOM, INC.
Reel/Frame 026516/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2011
From: SHULTS, MARK C.; UPDIKE, STUART J.; RHODES, RATHBUN K.
To: MARKWELL MEDICAL INSTITUTE, INC.
Reel/Frame 026489/0672 →
Continuity (3)
Continuation 09447227 · Nov 22, 1999
Division 08811473 · Mar 4, 1997
Related Publication 20110253533A1 · Oct 20, 2011